Glypressin

Glypressin is an injectable solution that contains the active ingredient terlipressin acetate. It is supplied in a sterile liquid form for intravenous administration and is classified as a vasopressin V1 receptor agonist. Glypressin is marketed in the European Union and is available by prescription only. The medication works by selectively stimulating V1 receptors to produce vasoconstriction, which helps manage specific circulatory complications.

Glypressin is prescribed for conditions that involve abnormal portal venous pressure and renal perfusion. It is used in clinical practice to control bleeding and improve organ function in the following situations:

- Management of acute esophageal variceal bleeding associated with portal hypertension. - Treatment of hepatorenal syndrome to enhance renal blood flow. - Reduction of portal venous pressure in patients with portal hypertension. - Adjunct therapy in liver transplantation settings to control bleeding. - Supportive care in severe circulatory shock when conventional vasopressors are insufficient.

Side effects of Glypressin vary in frequency and severity. Patients should be monitored for both common and serious reactions.

Common: - Headache - Nausea or vomiting - Abdominal pain - Flushing or warmth sensation - Hypertension (elevated blood pressure) - Peripheral edema

Serious: - Ischemic complications (e.g., myocardial ischemia, limb ischemia) - Severe hypertension leading to organ damage - Cardiac arrhythmias - Acute renal failure - Gastrointestinal necrosis - Allergic reactions such as anaphylaxis

Before initiating Glypressin therapy, clinicians should consider several precautionary measures to minimize risk. Important considerations include:

- Assess cardiovascular status, especially in patients with coronary artery disease. - Evaluate renal function; dose adjustments may be needed in renal impairment. - Monitor blood pressure closely during infusion. - Use caution in patients with peripheral vascular disease or a history of ischemic events. - Avoid use in patients with known hypersensitivity to terlipressin or related compounds. - Discontinue if signs of severe hypertension or ischemia develop.

Glypressin may interact with other medications, affecting its safety and efficacy. Interaction guidance is as follows:

Avoid: - Other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) that may exacerbate hypertension. - Monoamine oxidase inhibitors (MAOIs) due to potential additive pressor effects. - Drugs that significantly increase systemic vascular resistance.

Use with caution: - Antihypertensive agents, as they may counteract Glypressin's pressor action. - Diuretics, which can affect fluid balance and renal perfusion. - Beta‑blockers, which may mask tachycardia associated with hypertension. - Medications metabolized by hepatic pathways, given potential liver involvement in portal hypertension.